In a population of high-risk localized prostate cancer, PSMA PET/CT was shown to have a 27% greater accuracy than conventional imaging (92 vs 65%, p<0.0001), with a sensitivity of 85% and a 98% specificity (33). This evidence concerns the gene FOLH1 and prostate cancer.